文献速递淋巴瘤

伊沙佐米联合贝利司他通过NFE2L2依赖性凋亡协同治疗霍奇金与T细胞淋巴瘤

Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma.
PubMed 文献 · Br J Haematol · 2019-08-26

在霍奇金淋巴瘤(HL)和T细胞淋巴瘤(TCL)细胞系及原代肿瘤细胞中,伊沙佐米(ixazomib)处理引起蛋白酶体活性短暂抑制后完全恢复,伴NFE2L2(NRF2)上调的蛋白酶体基因表达诱导;贝利司他(belinostat)可下调NFE2L2和蛋白酶体基因表达。两药联合可阻断NFE2L2依赖的蛋白酶体恢复,延长蛋白酶体抑制,在伊沙佐米敏感和耐药细胞及原代细胞中产生协同活性,导致细胞死亡增加。

要点

  • 伊沙佐米在HL/TCL中诱导NFE2L2介导的蛋白酶体功能恢复
  • 贝利司他可下调NFE2L2及蛋白酶体基因表达
  • 联合用药阻断恢复并协同杀伤敏感及耐药细胞

核心结论

  • 伊沙佐米联合贝利司他的协同活性由抑制NFE2L2依赖性蛋白酶体恢复、延长蛋白酶体抑制并增加细胞死亡所介导。

研究设计与样本

  • 在HL和TCL细胞系(伊沙佐米敏感/耐药克隆)及原代肿瘤细胞中开展体外机制研究。

主要发现

  • 伊沙佐米处理的TCL和HL细胞出现蛋白酶体活性短暂抑制后完全恢复,伴蛋白酶体基因表达诱导,NFE2L2为突出上游调节因子。
  • 贝利司他处理Jurkat和L428细胞后NFE2L2及蛋白酶体基因表达下调(经qRT-PCR验证)。
  • CRISPR/Cas9介导Jurkat细胞NFE2L2敲低后,伊沙佐米处理较未处理对照细胞活力显著下降。
  • 伊沙佐米+贝利司他联合可消除NFE2L2、蛋白酶体基因表达及功能恢复,在敏感和耐药细胞系及原代细胞中产生协同药物活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ixazomib activity and transcriptomic analyses previously established in T cell (TCL) and Hodgkin (HL) lymphoma models predicted synergistic activity for histone deacetylase (HDAC) inhibitory combination. In this present study, we determined the mechanistic basis for ixazomib combination with the HDAC inhibitor, belinostat, in HL and TCL cells lines (ixazomib-sensitive/resistant clones) and primary tumour cells. In ixazomib-treated TCL and HL cells, transient inhibition followed by full recovery of proteasomal activity observed was accompanied by induction of proteasomal gene expression with NFE2L2 (also termed NRF2) as a prominent upstream regulator. Downregulation of both NFE2L2 and proteasomal gene expression (validated by quantitative real time polymerase chain reaction) occurred with belinostat treatment in Jurkat and L428 cells. In addition, CRISPR/Cas9 mediated knockdown of NFE2L2 in Jurkat cells resulted in a significant decrease in cell viability with ixazomib compared with untreated control cells. Using transcriptomic and proteasomal activity evaluation of ixazomib, belinostat, or ixazomib + belinostat treated cells, we observed that NFE2L2, proteasome gene expression and functional recovery were abrogated by ixazomib + belinostat combination, resulting in synergistic drug activity in ixazomib-sensitive and -resistant cell lines and primary cells. Altogether, these results suggest that the synergistic activity of ixazomib + belinostat is mediated via inhibition NFE2L2-dependent proteasomal recovery and extended proteasomal inhibition culminating in increased cell death.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Passero FC, Ravi D, McDonald JT, et al. Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma. Br J Haematol. 2019. PMID: 31452195. doi:10.1111/bjh.16160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。